Literature DB >> 7728151

Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype.

F Chen1, T Kishida, M Yao, T Hustad, D Glavac, M Dean, J R Gnarra, M L Orcutt, F M Duh, G Glenn.   

Abstract

von Hippel-Lindau disease (VHL) is an inherited neoplastic disease characterized by a predisposition to develop retinal angiomas, central nervous system hemangioblastomas, renal cell carcinomas, pancreatic cysts, and pheochromocytomas. The VHL gene was recently isolated by positional cloning. The cDNA encodes 852 nucleotides in 3 exons. The VHL gene is unrelated to any known gene families. We identified germline mutations in 85/114 (75%) of VHL families. Clinical heterogeneity is a well-known feature of VHL. VHL families were classified into 2 types based on the presence or absence of pheochromocytoma. The types of mutations responsible for VHL without pheochromocytoma (VHL type 1) differed from those responsible for VHL with pheochromocytoma (VHL type 2). Fifty-six % of the mutations responsible for VHL type 1 were microdeletions/insertions, nonsense mutations, or deletions; 96% of the mutations responsible for VHL type 2 were missense mutations. Specific mutations in codon 238 accounted for 43% of the mutations responsible for VHL type 2. The mutations identified in these families will be useful in presymptomatic diagnosis. The identification of mutations associated with phenotypes contributes to the understanding of fundamental genetic mechanisms of VHL disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7728151     DOI: 10.1002/humu.1380050109

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  126 in total

1.  First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.

Authors:  Anna Roma; Marco Maruzzo; Umberto Basso; Antonella Brunello; Rita Zamarchi; Elisabetta Bezzon; Fabio Pomerri; Stefania Zovato; Giuseppe Opocher; Vittorina Zagonel
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

2.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents.

Authors:  M T Sgambati; C Stolle; P L Choyke; M M Walther; B Zbar; W M Linehan; G M Glenn
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

4.  Ophthalmic pathology of genotypically confirmed von Hippel Lindau disease type 1.

Authors:  C M Knapp; G Woodruff; F Roberts
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

5.  A novel Von Hippel-Lindau case with germline mutation at codon 167 (CGG to TGG) having endocrine microadenomatosis of the pancreas.

Authors:  Tomotaka Akatsu; Koichi Aiura; Yasuhiro Ito; Masakazu Ueda; Kaori Kameyama; Masaki Kitajima
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

6.  Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.

Authors:  Johan Kugelberg; Jenny Welander; Francesca Schiavi; Ambrogio Fassina; Martin Bäckdahl; Catharina Larsson; Giuseppe Opocher; Peter Söderkvist; Patricia L Dahia; Hartmut P H Neumann; Oliver Gimm
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

7.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors:  Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

8.  Solid haemangioblastomas of the CNS: a review of 17 consecutive cases.

Authors:  Jens Rachinger; Rolf Buslei; Julian Prell; Christian Strauss
Journal:  Neurosurg Rev       Date:  2008-09-20       Impact factor: 3.042

9.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

10.  Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect.

Authors:  H Brauch; T Kishida; D Glavac; F Chen; F Pausch; H Höfler; F Latif; M I Lerman; B Zbar; H P Neumann
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.